Fig. 4: Associations between blood-based A/N groups with baseline and longitudinal cognitive performance and MRI-derived Alzheimer’s disease meta region of interest (AD meta ROI).
From: Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease
A, B Show the associations between A/N groups based on p-tau181 (A) and BD-tau (N) in blood with baseline and longitudinal cognitive performance (CERAD verbal memory recall and Trail Making Test-B (TMT-B)) in cohort 1 (Dementia Disease Initiation (DDI)). As compared to A-/N-, both A+/N- and A+/N+ profiles showed worse performance at baseline for CERAD, but only A+/N+ had worse performance for TMT-B. However, only A+/N+ profiles were associated with worsening over time for both tests. C Shows A/N groups associations with baseline and longitudinal AD meta-ROI, here only A+/N+ showed lower AD meta-ROI at baseline and increased atrophy over time. D, E Show the associations between A/N groups with baseline and longitudinal cognitive performance (Clinical Dementia Rating (CDR) and Mini Mental Status Examination (MMSE)) in cohort 3 (Biodegmar, Hospital del Mar, Barcelona memory clinic cohort). Here only A+/N+ profiles were associated with poorer scores on MMSE and CDR at baseline. While both A+/N- and A+/N+ showed higher CDRs over time, no longitudinal associations were seen for MMSE in any group. All plots display model predictions generated with the “ggeffects” R package. The lines display associations between the biomarker at -1SD, Mean and +1 SD and the dependent variable at baseline and over time. For more details see Supplementary Table 5.
